# GLP-1 Drugs and Headache: A Side Effect, and a Treatment

By Ruth Calder, Enforcement Editor (https://glpwatchdog.org/authors/ruth-calder) | Published: 2026-08-19 | Updated: 2026-10-30

Canonical page: https://glpwatchdog.org/research/glp1-headache-and-intracranial-pressure

> Headache is in the label’s adverse reactions table at 14% against 10% on placebo. A randomized trial using implanted pressure monitors also found a GLP-1 lowered intracranial pressure within hours.

## Key points

- Label: headache 14% on Wegovy against 10% on placebo, listed as a common reaction rather than in a warning section.
- Randomized trial, implanted pressure monitors: −5.7 cmCSF at 2.5h, −6.4 at 24h, and −5.6 at 12 weeks (P = 0.058).
- 15 women completed it, and it set significance at 0.10 rather than 0.05.
- The drop within hours is faster than weight loss can explain, which makes it the most interesting part.

These drugs cause headaches and are being studied as a treatment for one. The Wegovy label reports headache in **14%** of patients against 10% on placebo.[4] Meanwhile a randomized trial using pressure monitors implanted in the skull found a GLP-1 measurably lowered intracranial pressure in women with idiopathic intracranial hypertension, a condition whose defining symptom is headache.[1] A 2025 review titles this problem exactly: when these medications are therapeutic, and when they contribute to the symptom.[2]

## The side effect, first

Headache sits in the adverse reactions table of the label, not in a warning section, which places it among the common and generally self-limiting effects rather than the dangerous ones. In the adult weight-management trials it was reported by 14% of people on Wegovy and 10% on placebo.[4] That gap is real and it is narrow: with 10% reporting headache on placebo, most of the headaches reported on the drug would probably have happened without it.

Dehydration is the mechanism to know about, because it is the one you can do something about. Nausea, vomiting and reduced fluid intake all follow from [how these drugs work](https://glpwatchdog.org/learn/glp-1-medications/how-glp-1-drugs-work), and all of them cause headaches independently. Our [water intake calculator](https://glpwatchdog.org/tools/glp1-water-intake-calculator) works a target, and [how long side effects last](https://glpwatchdog.org/research/how-long-do-glp1-side-effects-last) covers the early-weeks pattern most of them follow.

## The condition where this gets interesting

Idiopathic intracranial hypertension is raised pressure around the brain with no tumor or clot to explain it. It causes severe headache and, because the pressure is transmitted to the optic nerve, it can take your sight. It can also cause [a ringing in time with the heartbeat](https://glpwatchdog.org/research/glp1-tinnitus-and-hearing). It is strongly associated with obesity, and it predominantly affects **women of childbearing age**, a population that overlaps heavily with the one being prescribed these drugs for weight.

Weight loss has long been the most effective treatment, which made a weight-loss drug an obvious thing to test. What was not obvious is that GLP-1 receptor signaling might lower intracranial pressure *directly*, which is what the preclinical work suggested.[1]

## What the trial did

The design is the impressive part. Rather than asking participants how their headaches felt, the researchers used telemetric catheters to monitor intracranial pressure continuously, giving an objective endpoint of a kind headache research rarely gets.[1] Adult women with active disease (pressure above 25 cmCSF and swelling of the optic disc) received exenatide or placebo, double-blind.

*Change in intracranial pressure against placebo. Brain, 2023. 16 women recruited, 15 completed.*

| Timepoint | Change (cmCSF) | P |
| --- | --- | --- |
| 2.5 hours | −5.7 ± 2.9 | 0.048 |
| 24 hours | −6.4 ± 2.9 | 0.030 |
| 12 weeks | −5.6 ± 3.0 | 0.058 |

Participants averaged 28 years old, a BMI of 38.1, and a starting pressure of 30.6 cmCSF.[1] A drop of roughly 6 from that baseline is not cosmetic, and it happened within hours. That is faster than any weight change could explain, and it is the strongest argument that something other than weight loss is doing the work.

> **Two things belong beside those P values.** Fifteen women completed the study. And the trial set its significance threshold a priori at **0.10** rather than the conventional 0.05. That is a defensible choice in a small early trial with an invasive endpoint, and one a reader should be told about. The two early results clear 0.05. The 12-week result (P = 0.058) clears only the trial’s own 0.10 bar, and that is part of how to weigh it.

## Migraine is a weaker story, and worth separating

A 2024 systematic review searched the whole GLP-1-and-pain literature, screening 833 records down to 42 studies across inflammatory pain, headache, neuropathic pain and visceral pain.[3] What it found for headache specifically is mechanistic: GLP-1 appears to be involved in migraine biology, and GLP-1 drugs show analgesic effects in *animal* models of inflammatory and neuropathic pain.

That is a reason to run trials, and the first small human studies are reviewed in [GLP-1s and migraine](https://glpwatchdog.org/research/glp1-and-migraine). It is not a reason to expect your migraines to improve, and the distinction matters because obesity and migraine are themselves linked. People with obesity who have migraine are at higher risk of it becoming chronic, so weight loss by any route may help without the drug doing anything to the migraine directly.[2]

> For migraine, the evidence is mechanistic and largely in animal models. There is no evidence that a GLP-1 will ease yours.

## If you get headaches on one of these

- **Fluids first.** The gastrointestinal effects dehydrate people, dehydration causes headache, and this is the part within your control.
- **Tell your prescriber if it is new, severe, or different from your usual pattern.** That is the standard advice for headache generally, and it is not weakened by being on a drug that lists headache.
- **Vision changes with headache are urgent.** Blurring, transient graying-out, or double vision alongside headache is how raised intracranial pressure presents, and it is a same-day problem rather than a wait-and-see one.
- **Do not self-treat a headache disorder with a weight-loss drug.** No GLP-1 is approved for any headache condition, and the IIH evidence is a 15-person trial.

For the separate question of what these drugs do to the eye, our [NAION and retinopathy article](https://glpwatchdog.org/research/glp1-eye-risk-naion-retinopathy) covers the vision risks that have their own evidence base, and [blurred vision on a GLP-1](https://glpwatchdog.org/research/glp1-blurred-vision) sorts everyday blur by cause.

## Frequently asked questions

### Do GLP-1 drugs cause headaches?

Headache is listed in the label's adverse reactions table: it was reported by 14% of adults on Wegovy against 10% on placebo. It sits among the common, generally self-limiting effects rather than in a warning section. Dehydration from nausea, vomiting and reduced fluid intake is a mechanism worth addressing because it is the one you can act on.

### Can a GLP-1 treat intracranial hypertension?

It is being studied, and the early evidence is interesting. A randomized trial using implanted pressure monitors found exenatide lowered intracranial pressure by about 5.7 cmCSF at 2.5 hours, 6.4 at 24 hours and 5.6 at 12 weeks in women with active idiopathic intracranial hypertension. Fifteen women completed that study and it set its significance threshold at 0.10, so it is a starting point rather than a basis for treatment.

### Will a GLP-1 help my migraines?

There is no evidence that it will. The migraine research is mechanistic and largely in animal models. Obesity and migraine are separately linked, so weight loss may help some people without the drug acting on migraine at all, which is a different claim.

### Why did the pressure drop so quickly?

That is the most intriguing part of the trial. The reduction appeared within 2.5 hours, far faster than any weight change could account for, which supports the preclinical suggestion that GLP-1 receptor signaling lowers intracranial pressure directly rather than through weight loss.

### When is a headache on a GLP-1 an emergency?

When it comes with vision changes (blurring, brief graying-out, or double vision). That combination is how raised intracranial pressure presents, and it needs same-day attention. A headache that is new, severe, or unlike your usual pattern also warrants contacting your prescriber.

## References

1. Mitchell JL, Lyons HS, Walker JK, et al. The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial. Brain. 2023. PMID: 36907221. https://pubmed.ncbi.nlm.nih.gov/36907221/
2. Ferreira ET, Garcia LMP, Londero RG. Headache and GLP-1 receptor agonists: when medications are therapeutic and when they contribute to the symptom. Arquivos de Neuro-Psiquiatria. 2025. PMID: 41145149. https://pubmed.ncbi.nlm.nih.gov/41145149/
3. Halloum W, Dughem YA, Beier D, Pellesi L. Glucagon-like peptide-1 (GLP-1) receptor agonists for headache and pain disorders: a systematic review. The Journal of Headache and Pain. 2024. PMID: 38997662. https://pubmed.ncbi.nlm.nih.gov/38997662/
4. Novo Nordisk Inc. WEGOVY (semaglutide) — US Prescribing Information, Section 6.1 Adverse Reactions (revised 06/2026). DailyMed (FDA-approved labeling). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b

---

Cite as: GLP Watchdog, Ruth Calder, "GLP-1 Drugs and Headache: A Side Effect, and a Treatment", published 2026-08-19, updated 2026-10-30. https://glpwatchdog.org/research/glp1-headache-and-intracranial-pressure

Canonical HTML page: https://glpwatchdog.org/research/glp1-headache-and-intracranial-pressure

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
